Friday, May 20, 2011
Wednesday, May 4, 2011
Artificial Lung amrket expands due to innovations
Innovation Expands Artificial Lung Market
Medtech Insight -- Advances in extracorporeal lung support devices are expanding the market for artificial lungs and are helping to extend and save the lives of patients with acute and chronic pulmonary disease.
At the Society of Thoracic Surgeons' annual meeting held in San Diego in January, researchers discussed new low-flow percutaneous catheters, advances in low-resistance membrane oxygenators, and improvements in pump designs that are enabling simpler, less invasive, and more portable solutions for treating patients with respiratory failure.
Wednesday, April 6, 2011
Lanka opens research, manufacturing unit for respiratory care
Lanka opens research, manufacturing unit for respiratory care
Akbar Pharmaceuticals, for the first time in Sri Lank inaugurated a fully equipped formulation development and manufacturing facility for respiratory care.
"Considerable investment in equipment has resulted in a state of the art facility. Among many expensive research and testing equipment installed at the ‘LINA’ formulation development and manufacturing facility for respiratory care located at Borupana Road, Ratmalana, is an artificial lung used for testing how deeply medication penetrates the lung when using inhalers and other delivery devices. A research and formulation team headed by the pioneer of development formulation for respiratory care Dr. Anil Gunathilake handles the sophisticated equipment in a sterile, climatically controlled environment, the company said in a statement.
The unit’s focus would be to produce pharmaceuticals to highest international standards while reducing the cost burden on patients, it said.
"Given the extraordinary concessions offered in the budget of 2011 for companies undertaking research, the company believes Sri Lanka’s national policy envisions promotion of such initiatives, convinced that its stated objective of building confidence in the minds of the Sri Lankan people about the quality of products made right here in this country can be achieved before long," it said
see more at
http://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=22354
Akbar Pharmaceuticals, for the first time in Sri Lank inaugurated a fully equipped formulation development and manufacturing facility for respiratory care.
"Considerable investment in equipment has resulted in a state of the art facility. Among many expensive research and testing equipment installed at the ‘LINA’ formulation development and manufacturing facility for respiratory care located at Borupana Road, Ratmalana, is an artificial lung used for testing how deeply medication penetrates the lung when using inhalers and other delivery devices. A research and formulation team headed by the pioneer of development formulation for respiratory care Dr. Anil Gunathilake handles the sophisticated equipment in a sterile, climatically controlled environment, the company said in a statement.
The unit’s focus would be to produce pharmaceuticals to highest international standards while reducing the cost burden on patients, it said.
"Given the extraordinary concessions offered in the budget of 2011 for companies undertaking research, the company believes Sri Lanka’s national policy envisions promotion of such initiatives, convinced that its stated objective of building confidence in the minds of the Sri Lankan people about the quality of products made right here in this country can be achieved before long," it said
see more at
http://www.island.lk/index.php?page_cat=article-details&page=article-details&code_title=22354
Thursday, March 31, 2011
gas exchange in the artificial lung
iLA Membrane Ventilator
A special hollow-fiber membrane assumes the function of pulmonary alveoli.
Effective and reliable: the iLA Membrane Ventilator® (Source: Novalung Support Registry 2008)
The iLA Membrane Ventilator® is the first artificial lung that breathes for the patient outside the body. It removes carbon dioxide outside of the lung, and is perfused by the heart like a natural organ. This relieves the patient’s lung by providing gas exchange support and reducing the workload for the breathing pump. The lung is given “Time to Heal“®.
The iLA Membrane Ventilator® is sometimes referred to in scientific articles as “pecla“ (pumpless extracorporeal lung assist) or ”AVCO2R“ (arterio-venous CO2 removal).
The iLA Membrane Ventilator® is sometimes referred to in scientific articles as “pecla“ (pumpless extracorporeal lung assist) or ”AVCO2R“ (arterio-venous CO2 removal).
Gas exchange via artificial alveoles
.jpg "iLA Membrane Ventilator")
A hollow-fiber membrane is responsible for gas exchange in the artificial lung, which measures only 14 by 14 cm, supporting or even replacing mechanical ventilation. The iLA Membrane Ventilator® is connected to the patient via two NovaPort® femoral cannulas in an arterio-venous circuit. The absence of a mechanical blood pump reduces the risk of inflammatory reactions.
How it works: effective and reliable
The iLA Membrane Ventilator® incorporates a heparin-coated hollow-fiber diffusion membrane and removes carbon dioxide effectively and reliably in a very short period of time to achieve the desired target, using low blood flows of approx. 1 L/min. This extrapulmonary ventilation can be controlled via the sweep gas flow. In cases of respiratory acidosis the pH is generally returned to normal physiological levels within a few hours. This can help protect the kidney and other organs and prevent multi-organ failure.
Easy to use and easy to care for
Positioning therapy and initial mobilization are possible with the iLA Membrane Ventilator thanks to the 360° rotating curve connectors. It is also been used for both inter-hospital and intra-hospital transport. The iLA Membrane Ventilator® was developed for temporary use in intensive-care patients and is approved in Europe for up to 29 days.
click to see the NovaLung official site
Monday, March 28, 2011
gas exchange in the artificial lung by NovaLung /Ila
Gas exchange via artificial alveoles
A hollow-fiber membrane is responsible for gas exchange in the artificial lung, which measures only 14 by 14 cm, supporting or even replacing mechanical ventilation. The iLA Membrane Ventilator® is connected to the patient via two NovaPort® femoral cannulas in an arterio-venous circuit. The absence of a mechanical blood pump reduces the risk of inflammatory reactions.
Friday, March 18, 2011
Novalung receives CE mark
Novalung receives CE mark for iLA activve With the new all-rounder for extrapulmonary lung support Novalung GmbH is the only company worldwide offering the complete portfolio for both pumpless and pump-driven lung support.
Novalung announces receiving CE mark approval for their new pump-driven iLA activve® lung support system. It will be launched in Europe with immediate effect.
Respiratory support with iLA activve® enables a treatment environment with awake, mobile patients instead of sedated patients on invasive mechanical ventilation that causes further damage to the lung and other organs. The iLA activve® is thus a major step towards replacing invasive mechanical ventilation.
Different patient populations and types of lung failure place varying demands on optimal respiratory support. To cover all extrapulmonary support needs with one system platform, the iLA activve® has been developed as a flexible all-rounder. The iLA activve® with veno-venous cannulation covers the full range of respiratory support, from highly effective carbon dioxide elimination to complete oxygenation. Core elements are the iLA Membrane Ventilator®, the only gas exchanger specifically designed for long-term respiratory support, and the iLA activve® pump which surpasses all previously available blood pumps in its performance, broad range of blood flow, and blood protection characteristics.
The iLA activve® system has been specifically configured to allow patients to move about during respiratory support. Therefore all necessary components are mounted on an easily movable trolley. Furthermore the iLA Membrane Ventilator® and the iLA activve® pump are height-adjustable via a quick-release handle. “This allows physicians, respiratory therapists and nurses to adjust the system to the patient’s individual needs, whether the patient is in bed, sits up or even walks”, explains Dr. Georg Matheis, Managing Director of Novalung.
The range of applications of the iLA Membrane Ventilator® technology has broadened substantially. While severe acute lunge failure (ARDS) was the typical indication in the early days, today exacerbations of chronic lung disease (COPD) comprise a growing application of the iLA Membrane Ventilator®. Novalung will launch several additional products for the iLA activve® platform throughout this year.
click for official Novalung
Novalung announces receiving CE mark approval for their new pump-driven iLA activve® lung support system. It will be launched in Europe with immediate effect.
Respiratory support with iLA activve® enables a treatment environment with awake, mobile patients instead of sedated patients on invasive mechanical ventilation that causes further damage to the lung and other organs. The iLA activve® is thus a major step towards replacing invasive mechanical ventilation.
Different patient populations and types of lung failure place varying demands on optimal respiratory support. To cover all extrapulmonary support needs with one system platform, the iLA activve® has been developed as a flexible all-rounder. The iLA activve® with veno-venous cannulation covers the full range of respiratory support, from highly effective carbon dioxide elimination to complete oxygenation. Core elements are the iLA Membrane Ventilator®, the only gas exchanger specifically designed for long-term respiratory support, and the iLA activve® pump which surpasses all previously available blood pumps in its performance, broad range of blood flow, and blood protection characteristics.
The iLA activve® system has been specifically configured to allow patients to move about during respiratory support. Therefore all necessary components are mounted on an easily movable trolley. Furthermore the iLA Membrane Ventilator® and the iLA activve® pump are height-adjustable via a quick-release handle. “This allows physicians, respiratory therapists and nurses to adjust the system to the patient’s individual needs, whether the patient is in bed, sits up or even walks”, explains Dr. Georg Matheis, Managing Director of Novalung.
The range of applications of the iLA Membrane Ventilator® technology has broadened substantially. While severe acute lunge failure (ARDS) was the typical indication in the early days, today exacerbations of chronic lung disease (COPD) comprise a growing application of the iLA Membrane Ventilator®. Novalung will launch several additional products for the iLA activve® platform throughout this year.
click for official Novalung
Wednesday, March 2, 2011
World Lung Foundation
Our Mission at the World Lung Foundation
To improve the lives of individuals across the world by strengthening community capacity to prevent and manage lung disease.
Since 2004, WLF has emerged as a dynamic public health organization with expertise in project management, capacity building, health communications and information, and operational research.click to the offical World Lung Foundation website
Subscribe to:
Posts (Atom)